French-Danish Clinical Trial Made Blood Cancer Disappear in 72% of Patients

11/11/2015 - 3 minutes

Onxeo is the French orphan-drug specialist in Oncology who has various pipelines for certain cancers. Now their phase I clinical trial of belinostat (trade name Beleodaq) combined with chemo for relapses in non-Hodgkin Lymphomas has shown an 89% response rate.

logo-onxeo-grandOriginally developed by TopoTarget (a biotech in Copenhagen) Belinostat is now under Onxeo’s portfolio (along with its Orphan drug designation and Fast Track Approval by the FDA) following a merger with BioAlliance Pharma last year.

Belinostat (trade name Beleodaq) has already been shown effective to treat relapses in Ovarian cancer when combined intravenously with chemotherapies (in this case carboplatin and Paclitaxel). Onxeo has therefore been looking to develop Beleodaq for use in relapses of non-Hodkin cancers too, such peripheral T-cell lymphomas (PTCL).

June results published in the Journal of Clinical Oncology showed Beleodaq achieved a 25.8% objective response rate when used alone to treat PTCL in the phase II ‘Belief’

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member